Krystexxa could well end up to be the Viagra of Savient.
Krystexxa could well end up to be the Viagra of Savient. It may possibly even be better? Competitors in the gout treatment arena work by lowering the amount of Uric acid as a percent. They still allow unacceptable amounts of uric acid to pass through the Kidneys, though not as much. That is small consolation because every drop of uric acid that flows through an already compromised kidney is one step closer to dialysis.
It turns out that if you can delay or improve the prospects for someone suffering from Kidney disease, and limit their need for dialysis you can save the healthcare system gobs of money. To say billions worldwide is not hyperbolic.
Yeah, it kind of is ("hyperbolic" I mean). Uric acid is a contributing factor in dialysis, but not the only factor and Krystexxa has a high percentage risk of infusion reaction which is also a limiting factor in its use. Not saying that there isn't a potential market there, but billions worldwide is probably an over-statement.
Since the only clinically approved treatment for Stage 5 Chronic Kidney Disease is transplant, at best Krystexxa would be useful as a holding measure for patients awaiting transplant and might augment but would not replace dialysis; that's STILL a big deal, don't get me wrong, and could well be worth millions in revenue, but "billions"? I don't think so.